These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 29223986)

  • 1.
    Charlton ME; Kahl AR; Greenbaum AA; Karlitz JJ; Lin C; Lynch CF; Chen VW
    J Natl Compr Canc Netw; 2017 Dec; 15(12):1484-1493. PubMed ID: 29223986
    [No Abstract]   [Full Text] [Related]  

  • 2. Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients.
    Yoon HH; Shi Q; Alberts SR; Goldberg RM; Thibodeau SN; Sargent DJ; Sinicrope FA;
    J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26160882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Socioeconomic Determinants of the Use of Molecular Testing in Stage IV Colorectal Cancer.
    Punekar SR; Griffin MM; Masri L; Roman SD; Makarov DV; Sherman SE; Becker DJ
    Am J Clin Oncol; 2021 Dec; 44(12):597-602. PubMed ID: 34753883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location.
    Sasaki K; Margonis GA; Wilson A; Kim Y; Buettner S; Andreatos N; Gani F; Amini N; Spolverato G; Pawlik TM
    Ann Surg Oncol; 2016 Oct; 23(11):3736-3743. PubMed ID: 27352204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of KRAS mutation, microsatellite instability, and tumor laterality on the prognosis of nonmetastatic colon cancer.
    Tran CG; Goffredo P; Mott SL; Hart A; You YN; Vauthey JN; Weigel RJ; Hassan I
    Surgery; 2022 Mar; 171(3):657-665. PubMed ID: 34865865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
    Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
    Sinicrope FA; Shi Q; Allegra CJ; Smyrk TC; Thibodeau SN; Goldberg RM; Meyers JP; Pogue-Geile KL; Yothers G; Sargent DJ; Alberts SR
    JAMA Oncol; 2017 Apr; 3(4):472-480. PubMed ID: 28006055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Associated With Guideline-recommended KRAS Testing in Colorectal Cancer Patients: A Population-based Study.
    Charlton ME; Karlitz JJ; Schlichting JA; Chen VW; Lynch CF
    Am J Clin Oncol; 2017 Oct; 40(5):498-506. PubMed ID: 25844824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of KRAS Mutation on the Presentation and Prognosis of Non-Metastatic Colon Cancer: an Analysis from the National Cancer Database.
    Scott A; Goffredo P; Ginader T; Hrabe J; Gribovskaja-Rupp I; Kapadia MR; Weigel RJ; Hassan I
    J Gastrointest Surg; 2020 Jun; 24(6):1402-1410. PubMed ID: 32128676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
    Taieb J; Kourie HR; Emile JF; Le Malicot K; Balogoun R; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Mulot C; Bouché O; Aparicio T; Michel P; Thaler J; Bridgewater J; Van Cutsem E; Perkins G; Lepage C; Salazar R; Laurent-Puig P;
    JAMA Oncol; 2018 Jul; 4(7):e173695. PubMed ID: 29167892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
    Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
    J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Site-specific Differences in Colonic Adenocarcinoma: KRAS Mutations and High Tumor Budding Are More Frequent in Cecal Adenocarcinoma.
    Landau MA; Zhu B; Akwuole FN; Pai RK
    Am J Surg Pathol; 2018 Mar; 42(3):351-358. PubMed ID: 29240583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer.
    Bleeker WA; Hayes VM; Karrenbeld A; Hofstra RM; Hermans J; Buys CC; Plukker JT
    Am J Gastroenterol; 2000 Oct; 95(10):2953-7. PubMed ID: 11051374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Better survival in right-sided versus left-sided stage I - III colon cancer patients.
    Warschkow R; Sulz MC; Marti L; Tarantino I; Schmied BM; Cerny T; Güller U
    BMC Cancer; 2016 Jul; 16():554. PubMed ID: 27464835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
    Roth AD; Tejpar S; Delorenzi M; Yan P; Fiocca R; Klingbiel D; Dietrich D; Biesmans B; Bodoky G; Barone C; Aranda E; Nordlinger B; Cisar L; Labianca R; Cunningham D; Van Cutsem E; Bosman F
    J Clin Oncol; 2010 Jan; 28(3):466-74. PubMed ID: 20008640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis.
    Bylsma LC; Gillezeau C; Garawin TA; Kelsh MA; Fryzek JP; Sangaré L; Lowe KA
    Cancer Med; 2020 Feb; 9(3):1044-1057. PubMed ID: 31856410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS Sequence Variation as Prognostic Marker in Patients With Young- vs Late-Onset Colorectal Cancer.
    Aljehani MA; Bien J; Lee JSH; Fisher GA; Lin AY
    JAMA Netw Open; 2023 Nov; 6(11):e2345801. PubMed ID: 38032636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data.
    Weiss JM; Schumacher J; Allen GO; Neuman H; Lange EO; Loconte NK; Greenberg CC; Smith MA
    Ann Surg Oncol; 2014 Jun; 21(6):1781-91. PubMed ID: 24643898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
    Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY
    World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Frequency of KRAS Codon 146 and FBXW7 Mutations in Thai Patients with Stage II-III Colon Cancer.
    Korphaisarn K; Pongpaibul A; Roothumnong E; Pongsuktavorn K; Thamlikitkul L; Anekpuritanang T; Poungvarin N; Thongnoppakhun W; Pithukpakorn M
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2319-2326. PubMed ID: 31450901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.